Section Arrow
Quote
COAG.NASDAQ
- Hemab Therapeutics Holdings, Inc.
Quotes are at least 15-min delayed:2026/05/06 14:07 EDT
Regular Hours
Last
 24.8
-0.2 (-0.80%)
Day High 
25.83 
Prev. Close
25 
1-M High
36.61 
Volume 
257.83K 
Bid
24.6
Ask
25
Day Low
23.475 
Open
25.25 
1-M Low
23.81 
Market Cap 
1.10B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High 36.61 
52-W Low 23.81 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.51/--
Enterprise Value
1.11B
Balance Sheet
Book Value Per Share
-4.00
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ERNAErnexa Therapeutics Inc.6.54+2.55+63.91%0PE
MNKDMannKind Corp3.595+0.735+25.70%143PE
AVTXAvalo Therapeutics21.68+5.42+33.33%-- 
IFRXInflaRx NV2.525+0.555+28.17%-- 
IBRXImmunityBio8.15+0.57+7.52%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.